Internal Medicine, Cardiovascular Disease · Boston, MA
NPI
1760597728
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
55 Fruit St, Yawkey 5b, Mgh
Boston, MA, 02114
Phone (617) 726-2709
Groups this clinician bills Medicare through
Medicare paid, 2024
$75K
915 services
Medicare patients, 2024
314
Average age 79
Drug cost, 2024
$15.3M
1,629 prescriptions
Company payments, 2025
$156K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Hanna K Gaggin was code 93000 (electrocardiogram), 306 times for 206 patients. In total Hanna K Gaggin billed 915 services in 16 codes, and Medicare paid $75K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-10-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 93000 Electrocardiogram | Office | 306 | 206 | $12.24 | $3,745 |
| 99215 Office E&M - Established | Office | 240 | 162 | $142.51 | $34K |
| 99232 Hospital E&M - Subsequent | Facility | 109 | 47 | $65.41 | $7,129 |
| 99214 Office E&M - Established | Office | 106 | 85 | $108.71 | $12K |
| 99233 Hospital E&M - Subsequent | Facility | 47 | 24 | $98.45 | $4,627 |
| 99205 Office E&M - New | Office | 25 | 25 | $189.15 | $4,729 |
| 99222 Hospital E&M - Initial | Facility | 18 | 18 | $108.87 | $1,960 |
| 99223 Hospital E&M - Initial | Facility | 17 | 17 | $143.24 | $2,435 |
| 99238 Hospital Discharge Management | Facility | 11 | 11 | $67.85 | $746 |
By year: 2022 $44K for 541 services; 2023 $68K for 837 services; 2024 $75K for 915 services.
Medicare prescription drug claims, 2024
In 2024, the drug Hanna K Gaggin prescribed most often to Medicare patients was Vyndamax (Tafamidis), with 581 prescriptions and refills. In total Hanna K Gaggin wrote 1,629 Medicare prescriptions that cost $15.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Vyndamax Tafamidis | 581 | 612 | 71 | $13.5M |
| Metoprolol Succinate Generic | 107 | 312 | 40 | $2,513 |
| Atorvastatin Calcium Generic | 101 | 298 | 36 | $1,590 |
| Jardiance Empagliflozin | 94 | 254 | 33 | $131K |
| Spironolactone Generic | 66 | 197 | 27 | $405 |
| Vyndaqel Tafamidis Meglumine | 63 | 63 | Under 11 | $1.3M |
| Eliquis Apixaban | 48 | 142 | 18 | $80K |
| Lisinopril Generic | 43 | 125 | 11 | $357 |
| Torsemide Generic | 38 | 108 | 15 | $1,484 |
| Entresto Sacubitril/Valsartan | 38 | 105 | 13 | $54K |
| Farxiga Dapagliflozin Propanediol | 37 | 93 | 14 | $51K |
| Losartan Potassium Generic | 35 | 105 | Under 11 | $492 |
| Eplerenone Generic | 34 | 102 | 13 | $2,720 |
| Furosemide Generic | 34 | 94 | 14 | $202 |
| Rosuvastatin Calcium Generic | 30 | 87 | 12 | $1,113 |
Brand drugs: 917 claims; generic drugs: 712 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Hanna K Gaggin $156K ($156K in general payments such as food, travel and fees) from 12 companies. The largest payer was Alexion Pharmaceuticals, Inc. with $48K.
| Company | Payments | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. AZN | 5 | $48K |
| Novo Nordisk AS NVO | 11 | $41K |
| Alnylam Pharmaceuticals Inc. ALNY | 15 | $16K |
| Merck Sharp & Dohme LLC MRK | 10 | $15K |
| BridgeBio Pharma, Inc. BBIO | 6 | $14K |
| Pfizer Inc. PFE | 7 | $11K |
| Novo Nordisk Inc NVO | 3 | $9,616 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $3,302 |
| Edwards Lifesciences Corporation EW | 1 | $91.43 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.